

**EMORY UNIVERSITY SCHOOL OF MEDICINE
CURRICULUM VITAE**

01/2019

Name **SAGAR LONIAL, MD**
Office Address Emory University School of Medicine
Winship Cancer Institute
1365 Clifton Road, Building C
Suite 3000
Atlanta, GA 30322
Phone (404) 727-5572
Fax (404) 778-1267
Email sloni01@emory.edu
Citizenship US Citizen

Current Titles and Affiliations

9/2011 - Present Professor of Hematology and Medical Oncology
Department of Hematology and Medical Oncology
Emory University School of Medicine
Winship Cancer Institute
Atlanta, GA

7/2001 – Present Founder and Course Director
Annual Updates in Hematology & Oncology
Winship Cancer Institute
Atlanta, GA

Clinical Appointments

2/2016 – Present Chair
Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, Ga

2/2015 – Present Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, GA

2/2015 – 2/2016 Executive Vice Chair
Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA

11/2009 – 2/2016 Vice Chair for Clinical Affairs
Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA

9/2006 – Present Director of Translational Research, B-Cell Malignancy
Program
Department of Hematology and Medical Oncology
Atlanta, GA

9/2006 – 2010 Co-Director, Phase I Program
Department of Hematology and Medical Oncology

Emory University School of Medicine
Winship Cancer Institute
Atlanta, GA

Previous Academic and Professional Appointments

2010 – 2015	Medical Director, Phase I Program Winship Cancer Institute Emory University School of Medicine Atlanta, GA
9/2006 – 8/2011	Associate Professor of Hematology and Medical Oncology Emory University School of Medicine Winship Cancer Institute Atlanta, GA
6/2007 – 6/2009	Associate Director, Hematology -Oncology Fellowship Program Emory University School of Medicine Winship Cancer Institute Atlanta, Georgia
7/2000 – 8/2006	Assistant Professor Emory University School of Medicine Winship Cancer Institute Atlanta, Georgia

Medical License State of Georgia

Specialty Board Certifications

1995	American Board of Internal Medicine
1996	Diplomat National Board of Medical Examiners
2000	American Board of Internal Medicine-Hematology
2000	American Board of Internal Medicine-Oncology

Education

1989 - 1993	M.D. University of Louisville School of Medicine Louisville, Kentucky Clinical Honors - Neurology, Dermatology
1985 - 1989	B.A., The Johns Hopkins University, Baltimore, Maryland Major: Biology and Philosophy

Postgraduate Training

7/1997 – 7/2000	Fellow Hematology/Oncology Emory University School of Medicine Atlanta, Georgia
1999 - 2000	Chief Fellow Hematology/Oncology Program Emory University School of Medicine Atlanta, Georgia
1/1997 - 6/1997	Chief Resident Department Of Medicine at Baylor College of Medicine St. Luke's Episcopal Hospital

7/1996 – 12/1997 Houston, Texas
Chief Resident
Baylor College of Medicine
Ben Taub General Hospital
Houston, Texas

7/1996 – 6/1997 Houston, Texas
Attending Staff
Department of Internal Medicine at Baylor College of
Medicine
Ben Taub General Hospital
Houston, Texas

6/1993 – 6/1996 Houston, Texas
Internship/Residency
Baylor College of Medicine
Houston Texas

Committee Memberships

National and International

Multiple Myeloma Research Foundation: Steering Committee Member 7/06-7/08,
12/09 – present
Multiple Myeloma Research Foundation Steering Committee Chair 1/13- present
ECOG Myeloma Committee Vice Chair, 6/07-present
IMF Scientific Board of Advisors 5/08 – present
American Society of Hematology Committee on Education Affairs 2007-2010
American Society of Hematology Committee on Communications 2008-2010
American Society of Hematology Journals Committee 2008-2010
American Society of Hematology Ad Hoc Scientific Committee on Plasma Cell
Neoplasia. 2010 – 2013
American Society of Hematology Bridge Grant Study Section Member 2015-
American Society of Hematology Asch Scholar Grant Study Section 2014-
Center for International Blood & Marrow Transplant Research (CIBTMR)
Committee Co-Chair 2009 - 2013
Panorama 1 Steering Committee – Novartis 2010 - present
International Myeloma Society Board of Directors 2011-present
Program Committee ASCO 2013-2016 (Plasma cell and Lymphoma Track)
Cancer Education Committee on the Hematologic Malignancies-Plasma Cell
Dyscrasia Track 6/15-
Myeloma UK External Advisor 1/2012-current
External Advisor, Grand Family Myeloma Program UCSF 2011-2014
External Advisor City of Hope Myeloma Program 2015-

Institutional

EHC Marketing Executive Committee	4/14-Present
EHC Board of Directors	6/14-2/16
EHC IT Oversight Committee	1/14-6/14
Deans Budget oversight Committee	1/18- Present
Physician Compensation Committee	9/17-Present

Johns Hopkins University

1988 – 1989 Student Member-Committees on Undergraduate Admissions

1987 - 1989 Resident Advisor-Freshman Dormitories

Emory University School of Medicine

8/06 - present Hematology-Oncology Fellowship Evaluation Committee
2010 - present Pediatric Hematology Oncology RG Grant Review Committee
2007 - present Hematology-Medical Oncology DSMC Committee:
2009 - present Hematology-Medical Oncology Departmental Research Committee:
2011 Winship Cancer Institute Business Planning Steering Committee:
2011 Credentials and Medical Executive Committee:

Editorships and Editorial Boards

2003 - 2010 *American Journal of Clinical Oncology*
4/2004 Guest Editor, "Proceedings of 3rd Annual update in Hematology and Oncology", Supplement to *Seminars in Oncology*
3/2006 - Present Associate Editor, *Clinical Lymphoma and Myeloma*
10/2010 - Present Myeloma Section Editor
11/2010 -1/2015 *Leukemia* Editorial Board,
1/2011 – 1/2016 *Leukemia & Lymphoma* Editorial Board
1/2011 - Present *Journal of Clinical Oncology* Editorial Board
6/2015 – Present *Journal of Oncology Practice*, Associate Editor
6/2017 – Present *Cancer*, Associate Editor

Invited and Ad Hoc Manuscript Reviewer

Blood, 2002 -
Cancer Research, 2005 -
Clinical Cancer Research, 2005 -
Haematologica, 2005 -
American Journal of Hematology, 2005 -
The Haematology Journal, 2005 -
Bone Marrow Transplant, 2004 -
Supportive Cancer Therapy, 2004 -
Molecular Cancer Therapeutics, 2007
New England Journal of Medicine, 2008 -
Lancet, 2008 -
British Journal of Haematology, 2005 -

Honors and Awards

1989 - 1993 Young Trustee-Johns Hopkins University Board of Trustees
1996 Henry B. Macintosh Award Best Resident in Internal
Medicine
1995 Houston Society of Internal Medicine
2005 MMRC Center of the Year Award
2012 MMRF recognition as one of 15 "MMRF Innovators"
2012 Celgene Young Investigator Award
2017 Indo American Cancer Association (IACA) Life Time
Achievement Award

Professional Society Memberships

1995- Present	American College of Physicians ACP
1999- Present	American Society of Hematology ASH
1999- Present	American Society of Clinical Oncology ASCO
2001- Present	American Society of Bone Marrow Transplantation
ASBMT	
2001- Present	American Association for Cancer Research AACR
2010 – Present	International Myeloma Society IMS

Research focus

A major focus of the Lonial lab is the development of novel single agents or combinations of novel agents with the intent of more effective targeted therapy for myeloma and lymphoma.

Research Experience

1985 - 1989	Adult Leukemia Service Johns Hopkins Oncology Center Director: P.J. Burke and Judy Karp, M.D. Professor Johns Hopkins University School of Medicine
-------------	--

Projects:

	1) Effects of HMBA on myeloid cell differentiation 2) Effects of cytokines on normal, AML, and CML Bone marrow growth and maturation.
1989 - 1990	Bone Marrow Transplant Research Lab Brown Cancer Center Louisville, Kentucky Supervised by: Don Stephens, M.D. Associate Professor, University of Louisville School of Medicine

Project:

1998-2000	Effect of IL-3 on nerve growth factor mRNA expression Stem Cell Biology Lab Associate Professor of Medicine, Division of Hematology-Oncology Emory University School of Medicine
-----------	--

Projects:

	1) V β repertoire changes after bone marrow transplantation 2) Post-transplant adoptive immunity using vaccination 3) Dendritic cell subtypes in allogeneic transplantation 4) The effect of fludarabine on human donor lymphocytes 5) Dendritic cell subsets as enhancers of donor CTL's
2000 – 2006	Blood Cell Therapy Lab Emory University School of Medicine Winship Cancer Institute
2006 – Present	Translation B-Cell Malignancy Lab Emory University School of Medicine Winship Cancer Institute

- Projects:**
- 1) Dendritic Cell purification and modulation
 - 2) The effects of molecular targeted agents on myeloma and lymphoma cell growth and proliferation. Mechanisms of synergy and function
 - 3) Modulation of PI3K signaling in Myeloma
 - 4) Role of 14-3-3 Zeta in plasma cell biology

Grant Support – Active

Federally funded:

NIH R01CA134786-01A2 08/01/2010 – 05/31/2019 1.2 Person
Months

Subcontract to USC – W. Cozen (PI) \$101,808

The major goal of this project is to conduct a Genome Wide Admixture Scan of Multiple Myeloma in African Americans.

Role: Consortium Principal Investigator

Private Foundation funded:

Pilot Study - **DFCI Sub-Contract** 04/01/2007 – 12/31/2019 1%
\$64,000

Title: "Bortezomib, Lenolidomide & Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma."

Role: Consortium Principal Investigator

Protocols Written (Open and Completed)

1. A Phase I study testing the efficacy and Safety of a novel combination (VTEPA) for the treatment of relapsed and refractory lymphoma. *Completed*
2. A Randomized study comparing the dendritic cell content of autologous stem cell grafts using either G-CSF or the combination of G-CSF+GM-CSF. *Completed*
3. A Randomized trial comparing the use of G-CSF vs G-CSF + GM-CSF for the mobilization of allogeneic peripheral blood stem cell grafts and the effects on dendritic cell content and immune recovery post transplant. *Completed.*
4. Combination High dose melphalan with Bortezomib. A dose and schedule finding. Closed
5. Combined Farnesyl Transferase Inhibition with Proteasome Inhibition: A phase I trial of bortezomib and tipifarnib for relapsed multiple myeloma. Closed.
6. A Phase 1 protocol of SF1126 for relapsed or refractory multiple myeloma. Closed.
7. A phase I study of LBH589+lenalidomide for patients with relapsed/refractory myeloma. closed
8. A phase I study of the combination of HuLuc 63 + lenalidomide in relapsed/refractory myeloma. Closed.
9. A Phase I study of STA-9090 +/- Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma.

Lectureships, Seminar Invitations, and Visiting Professorships

1. IMF Boca Raton Patient & Family Seminar 5/15
2. Great Debates & Updates in Hematologic Malignancies (New York) 5/15
3. Asheville Hematologic Malignancies Symposium 6/15
4. First Annual Immuno-oncology in Myeloma Workshop (Houston) 7/15

5. Emil J Freireich Leukemia Hematology Grand Rounds (Houston) 7/15
6. 10th Annual New Orleans Summer Cancer Meeting (New Orleans, LA) 8/15
7. SCOA Educational Program (Columbia, SC) 8/15
8. Society of Hematology and Oncology (SOHO) 2 talks and session Chair 9/15
9. Twin Cities Hematologic Malignancies Symposium (Minneapolis) 10/15
10. 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow (New York) 11/15
11. 1st annual PRIMO meeting, Maui Hawaii, Co-Chair and Speaker 1/16
12. 2nd World Congress on Controversies in Multiple Myeloma (COMy) Paris France 4/16
13. 2nd Annual Immuno-oncology in Myeloma Workshop. Boston, MA 5/16
14. Pan Pacific Lymphoma Conference, Kuai, 7/16
15. 2016 Comprehensive Board Review in Hematology and Medical Oncology Houston, TX 9/16
16. European School of Hematology 3rd International Conference on Multiple Myeloma, Co-Chair and Speaker. Milan 10/16
17. PRIMO meeting, Maui Hawaii, Co-Chair and Speaker 1/17
18. 2017 Comprehensive Board Review in Hematology and Medical Oncology Houston, TX 9/17
19. IMW Education Symposium, Washington DC, 10/17
20. ASCO Satellite Symposium, June 2017

BIBLIOGRAPHY

Published and Accepted Research Articles in Refereed Journals

1. Mina R, Joseph NS, Kaufman JL, Gupta VA, Heffner LT, Hofmeister CC, Boise LH, Dhodapkar MV, Gleason C, Nooka AK, **Lonial S**. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. *Cancer* 6.537. 2018 Oct 17.
2. **Lonial S**, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Dimopoulos MA, *Cancer* 6.537. 2018 Oct 15;124(20):4032-4043.
3. San-Miguel JF, Echeveste Gutierrez MA, Špicka I, Mateos MV, Song K, Craig MD, Bladé J, Hájek R, Chen C, Di Bacco A, Estevam J, Gupta N, Byrne C, Lu V, van de Velde H, **Lonial S**. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. *Haematologica* 9.090. 2018 Sep;103(9):1518-1526.
4. Richardson PG, Schlossman RL, Roy AN, Panneerselvam A, Acharyya S, Sopala M, **Lonial S**. Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥ 2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial. *Br J Haematologica* 9.090. 2018 Jun;181(5):628-636.
5. Gu Y, Xu K, Torre C, Samur M, Barwick BG, Rupji M, Arora J, Neri P, Kaufman J, Nooka A, Bernal-Mizrachi L, Vertino P, Sun SY, Chen J, Munshi N, Fu H, Kowalski J, Boise LH, **Lonial S**. 14-3-3 ζ binds the proteasome, limits proteolytic function and

- enhances sensitivity to proteasome inhibitors. *Leukemia* 10.0223. 2018 Mar;32(3):744-751.
6. Shah JJ, Kaufman JL, Zonder JA, Cohen AD, Bensinger WI, Hilder BW, Rush SA, Walker DH, Tunquist BJ, Litwiler KS, Ptaszynski M, Orlowski RZ, **Lonial S**. A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma. *Cancer* 6.537. 2017 Dec 1;123(23):4617-4630.
 7. Miller A, Asmann Y, Cattaneo L, Braggio E, Keats J, Auclair D, **Lonial S**; MMRF CoMMpass Network, Russell SJ, Stewart AK. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma. *Blood Cancer J* 8.125. 2017 Sep 22;7(9):e612
 8. Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Iftikhharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, **Lonial S**. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. *Blood* 15.132. 2017 Aug 24;130(8):974-981.
 9. Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, Orlowski R, Supko JG, Tamang D, Yang M, Jones SS, Wheeler C, Markelewicz RJ, **Lonial S**. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. *Clinical Cancer Research* 10.199. 2017 Jul 1;23(13):3307-3315
 10. Ramsey BW, Nepom GT, **Lonial S**. Academic, Foundation, and Industry Collaboration in Finding New Therapies. *N Engl J Med*. 79.260. 2017 May 4;376(18):1762-1769.
 11. Tariman JD, Gleason C, Faiman B, Doss D, Catamero D, Bishop-Royse J, Katz M, Kurtin S, Moran D; IMF Nurse Leadership Board, **Lonial S**. Lack of health maintenance examinations and risk in myeloma patients. *Cancer Med* 3.362. 2016 Jul;5(7):1425-35.
 12. **Lonial S**, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. *Lancet* 47.831. 2016 Apr 9;387(10027):1551-60.
 13. Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, **Lonial S**. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. *Clin Cancer Res* 9.619. 2016 Jan 1;22(1):34-43.
 14. Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, White D, Reece DE, Benboubker L, Zonder J, Tsao LC, Anderson KC, Bleickardt E, Singhal AK, **Lonial S**; 1703 study investigators. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. *Lancet Haematology* 6.671. 2015 Dec;2(12):e516-27.

15. **Lonial S**, Boise LH, Kaufman J. How I treat high-risk myeloma. *Blood* 11.847. 2015 Sep 24;126(13):1536-43.
16. **Lonial S**, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. *N Engl J Med*. 59.912. 2015 Aug 13;373(7):621-31
17. Nooka AK, Kastiris E, Dimopoulos MA, Lonial S. Treatment options for relapsed and refractory multiple myeloma. *Blood* 10.452. 2015 May 14;125(20):3085-99.
18. Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, **Lonial S** Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. *Blood* 10.452. 2014 Aug 14;124(7):1038-46.
19. Gu Y, Kaufman JL, Bernal L, Torre C, Matulis SM, Harvey RD, Chen J, Sun SY, Boise LH, **Lonial S**. MLN4924, an investigational NAE inhibitor, suppresses AKT and mTOR signaling pathway through up regulating REDD1 in human myeloma cells. *Blood*. 10.452. 2014 Apr 8.
20. Nooka AK, Kaufman JL, Muppidi S, Langston A, Heffner LT, Gleason C, Casbourne D, Saxe D, Boise LH, **Lonial S**. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. *Leukemia* 10.431. 2014 Mar;28(3):690-3.
21. **Lonial S**, Anderson KC. Association of response endpoints with survival outcomes in multiple myeloma. *Leukemia* 10.431. 2014 Feb;28(2):258-6

Published Review Articles (peer-reviewed)

1. Köhler M, Greil C, Hudecek M, **Lonial S**, Raje N, Wäsch R, Engelhardt M. Current developments in immunotherapy in the treatment of multiple myeloma. *Cancer*. 2018 Feb 6.
2. Richardson P, Roy A, Acharyya S, Panneerselvam A, Mendelson E, Günther A, **Lonial S**, Einsele H. Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent. *Expert Rev Hematol*. 2017 Oct;10(10):933-939.
3. Joseph NS, Gentili S, Kaufman JL, **Lonial S**, Nooka AK. High-risk Multiple Myeloma: Definition and Management. *Clin Lymphoma Myeloma Leuk*. 2017 Jul;17S:S80-S87
4. Richardson PG, Moreau P, Laubach JP, Maglio ME, **Lonial S**, San-Miguel J. Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. *Pharmacol Res*. 2017 Mar;117:185-191.
5. Laubach JP, San-Miguel JF, Hungria V, Hou J, Moreau P, **Lonial S**, Lee JH, Einsele H, Alsina M, Richardson PG. Deacetylase inhibitors: an advance in myeloma therapy? *Expert Rev Hematol*. 2017 Mar;10(3):229-237.
6. Schlafer D, Shah KS, Panjic EH, **Lonial S**. Safety of proteasome inhibitors for treatment of multiple myeloma. *Expert Opin Drug Saf*. 2017 Feb;16(2):167-183
7. Richardson PG, Harvey RD, Laubach JP, Moreau P, **Lonial S**, San-Miguel JF. Panobinostat for the treatment of relapsed or relapsed/refractory multiple

- myeloma: pharmacology and clinical outcomes. *Expert Rev Clin Pharmacol*. 2016;9(1):35-48.
8. **Lonial S**. Treatment of MM: Upcoming Novel Therapies. *Cancer Treat Res*. 2016;169:195-205.
 9. Neri P, Bahlis NJ, **Lonial S**. New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma. *Clin Cancer Res*. 2016 Dec 15;22(24):5959-5965.
 10. Hofmeister CC, **Lonial S**. How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma. *J Clin Oncol*. 2016 Dec 20;34(36):4421-4430
 11. Orlowski RZ, **Lonial S**. Integration of Novel Agents into the Care of Patients with Multiple Myeloma. *Clin Cancer Res*. 2016 Nov 15;22(22):5443-5452.
 12. **Lonial S**, Kaufman J, Reece D, Mateos MV, Laubach J, Richardson P. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. *Expert Opin Biol Ther*. 2016 Oct;16(10):1291-301.
 13. Xia C, Ribeiro M, Scott S, **Lonial S**. Daratumumab: monoclonal antibody therapy to treat multiple myeloma. *Drugs Today*. 2016 Oct;52(10):551-560
 14. Nooka AK, **Lonial S**. New Targets and New Agents in High-Risk Multiple Myeloma. *Am Soc Clin Oncol Educ Book*. 2016;35:e431-41.
 15. Nooka AK, **Lonial S**. Is Maintenance Therapy for Everyone? *Clin Lymphoma Myeloma Leuk*. 2016 Aug;16 Suppl:S139-44.
 16. Nooka AK, **Lonial S**. Novel Combination Treatments in Multiple Myeloma. *Oncology (Williston Park)*. 2016 May;30(5):451-65.
 17. **Lonial S**, Nooka AK. Myeloma Is Not a Single Disease. *J Oncol Pract*. 2016 Apr;12(4):287-92.
 18. **Lonial S**, Durie B, Palumbo A, Miguel JS . Monoclonal antibodies in the treatment of multiple myeloma: Current status and future perspectives. *Leukemia*. 2016 Mar;30(3):526-35.
 19. **Lonial S**. Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38. *Cancer J*. 2016 Jan-Feb;22(1):3-6
 20. **Lonial S**. Monoclonal antibodies in multiple myeloma: data from the 2015 ASH meeting. *Clin Adv Hematol Oncol*. 2016 Feb;14(2):82-4.
 21. Koff JL, **Lonial S**. Emerging treatments in Castleman disease - a critical appraisal of siltuximab. *Biologics*. 2016 Jan 25;10:9-15.
 22. **Lonial S**, Nooka AK. Novel combination approaches for myeloma. *Hematology Am Soc Hematol Educ Program*. 2015;2015:286-93.
 23. Nooka AK, Kastiris E, Dimopoulos MA, **Lonial S**. Treatment options for relapsed and refractory multiple myeloma. *Blood*. 2015 Apr 2.
 24. Gentili S, **Lonial S**. Relapsed and refractory multiple myeloma: new therapeutic strategies. *Hematol Oncol Clin North Am*. 2014 Oct;28(5):861-90.
 25. Usmani SZ, **Lonial S**. Novel Drug Combinations for the Management of Relapsed/Refractory Multiple Myeloma *Clin Lymphoma Myeloma Leuk*. 2014 Sep;14S:S71-S77.
 26. Laubach JP, Voorhees PM, Hassoun H, Jakubowiak A, **Lonial S**, Richardson PG. Current strategies for treatment of relapsed/refractory multiple myeloma. *Expert Rev Hematol*. 2014 Feb;7(1):97-111.
 27. Eicher DM, **Lonial S**, Cavallo F, Palumbo A, Nair B, Waheed S, Hofmeister C, Rogers HJ. High-risk myeloma: when to transplant-or not. *Semin Oncol*. 2014 Feb;41(1):e1-9.